ライフサイエンスコーパス: paclitaxel

1 king of (14)C-labeled or fluorescent-labeled paclitaxel.

2 onizing radiation and chemotherapeutic drug, paclitaxel.

3 raction that enables antibody coating of nab-paclitaxel.

4 sitive to the microtubule stabilizing agent, paclitaxel.

5 There was a trend toward superior OS for paclitaxel.

6 m(2) intravenously) or matching placebo plus paclitaxel.

7 n of nanocarriers that deliver irinotecan or paclitaxel.

8 the cancers noted above that respond to nab-paclitaxel.

9 xtremely water insoluble drugs, curcumin and paclitaxel.

10 ne, cisplatin, methotrexate, doxorubicin and paclitaxel.

11 by cancer patients receiving treatment with paclitaxel.

12 1 overexpression enhanced sensitivity to nab-paclitaxel.

13 as evidence of a favourable interaction with paclitaxel.

14 thic pain induced by the cancer chemotherapy paclitaxel.

15 s paclitaxel and 262 to receive placebo plus paclitaxel.

16 ity for invasion and increased resistance to paclitaxel.

17 osensitizers, gold nanoparticles (1.19), and paclitaxel (1.32).

18 Albumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1

19 In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong in

20 er cisplatin (50 mg/m(2) on day 1 or 2) plus paclitaxel (135 mg/m(2) or 175 mg/m(2) on day 1) or topo

21 with drug-eluting stents (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus).

22 s or carboplatin area under the curve 6 plus paclitaxel 175 mg/m(2) every 3 weeks).

23 (physician's choice: vinflunine 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intrave

24 or topotecan (0.75 mg/m(2) on days 1-3) plus paclitaxel (175 mg/m(2) on day 1) with or without intrav

25 tandard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m(2) of body surface area] and carbop

26 th treatment-naive stage IV NSCLC to receive paclitaxel (200 mg/m(2); every 21 days) plus carboplatin

27 d to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.

28 %), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine

29 patients were treated with nCRT (carboplatin/paclitaxel/41.4 Gy) followed by esophagectomy.

30 between cisplatin-etoposide and carboplatin-paclitaxel (58% vs 56%; P = .26), respectively.

31 ndomly assigned (1:1) to receive intravenous paclitaxel 80 mg/m(2) (days 1, 8, 15) with either ipatas

32 axel 75 mg/m(2) every 3 weeks or intravenous paclitaxel 80 mg/m(2) weekly).

33 the efficacy of pazopanib 800 mg orally with paclitaxel (80 mg/m(2) days 1, 8, and 15 every 28 days)

34 eive oral olaparib (100 mg twice daily) plus paclitaxel (80 mg/m(2) intravenously) or matching placeb

35 mg once daily) or placebo, plus intravenous paclitaxel (80 mg/m(2) on days 1, 8, 15, and 22) in 28 d

36 progression-free survival was 4.1 months for paclitaxel (80% CI, 3.0 to 5.6 months) and 3.1 months fo

37 Median OS was 8.0 months for paclitaxel (80% CI, 6.9 to 9.7 months) and 4.7 months fo

38 targeting S100A4 nuclear import by low-dose paclitaxel, a microtubule-stabilizing agent, inhibits ch

39 Nab-paclitaxel, a nanoparticle conjugate of paclitaxel to hu

40 Previously we described three nab-paclitaxel (Abraxane) nanoparticles coated with commerci

41 Lesion composition affected paclitaxel absorption and distribution in cadaveric huma

42 alently bound to the albumin scaffold of nab-paclitaxel (ABX).

43 abine plus nanoparticle albumin-bound (NAB) -paclitaxel (adequate comorbidity profile) should be offe

44 atment consisted of weekly 80-mg/m2 doses of paclitaxel administered concurrently with trastuzumab in

45 as 3.9 months longer than that observed with paclitaxel administered every 3 weeks (14.2 vs. 10.3 mon

46 hen randomly assigned them to receive either paclitaxel, administered intravenously at a dose of 175

47 nder the curve [AUC] of 6) for six cycles or paclitaxel, administered weekly at a dose of 80 mg per s

48 g seribantumab plus paclitaxel compared with paclitaxel alone (PFS HR, 0.37; 95% CI, 0.18 to 0.76; P

49 with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or

50 rrent standard of alcohol lavage followed by paclitaxel alone.

51 om previous trials using alcohol followed by paclitaxel alone.

52 tly decreased tumor weight than the control, paclitaxel-alone, or itraconazole-alone groups.

53 Despite its beneficial effects on cancer, paclitaxel also damages healthy tissues, most prominentl

54 Compared with other agents, paclitaxel also displayed a unique prolonged exposure in

55 c basis of kinetic stabilization by the MTAs paclitaxel, an assembly promoter, and vinblastine, a dis

56 nd they have both progressed into humans for paclitaxel, an important yet poorly water-soluble chemot

57 his study, we demonstrate that codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalco

58 domly assigned: 263 to receive olaparib plus paclitaxel and 262 to receive placebo plus paclitaxel.

59 ion of four drugs (palbociclib, gemcitabine, paclitaxel and actinomycin D) to illustrate potential ap

60 formula; every 21 days) or carboplatin plus paclitaxel and bevacizumab (15 mg/kg; every 21 days), ei

61 f the second week of first cycle carboplatin-paclitaxel and bevacizumab (CPB) treatment.

62 s of induction chemotherapy with 175 mg/m(2) paclitaxel and carboplatin (target area under the curve

63 g progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks am

64 posed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-fre

65 y of two front-line chemotherapeutic agents (paclitaxel and cisplatin) are described within three dis

66 all-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide.

67 roups were then infused with an admixture of paclitaxel and gemcitabine.

68 mly assigned to cisplatin and gemcitabine or paclitaxel and gemcitabine; nonsquamous patients receive

69 to platinum therapy (median OS, 7.6 months [paclitaxel and gemcitabine] v 10.7 months [cisplatin and

70 We compared the effects of the drugs paclitaxel and ixabepilone that bind along the lengths o

71 Collectively, these results suggest that paclitaxel and ixabepilone, which bind along the lengths

72 V and amplitude, with greater deficits after paclitaxel and lesser deficits after ixabepilone.

73 re effective in determining the transport of paclitaxel and methotrexate in brain tumour.

74 V-nAb-PTX also augmented the accumulation of paclitaxel and MSV in the liver, specifically in macroph

75 Simultaneous treatment with paclitaxel and Notch inhibitors achieves sustained suppr

76 predictive biomarker for the response to nab-paclitaxel and other albumin-based cancer therapeutic dr

77 for toxicity occurred in 7.8% and 23.1% for paclitaxel and pazopanib, respectively.

78 (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pe

79 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pem

80 atients received cisplatin and pemetrexed or paclitaxel and pemetrexed.

81 xel improves clinical outcomes compared with paclitaxel and placebo in patients with recurrent or met

82 8 enhanced the intratumoral concentration of paclitaxel and promoted apoptosis, thereby potently inhi

83 0% +/- 2.67% and 60.62% +/- 4.35% release of paclitaxel and rubone at 24 hours.

84 Paclitaxel and rubone combination therapy inhibited tumo

85 Systemic administration of micelles carrying paclitaxel and rubone inhibited orthotopic prostate tumo

86 were 9.70% +/- 0.10% and 5.34% +/- 0.02% for paclitaxel and rubone, respectively, controlling a drug

87 ance of 4T1 breast cancer stem-like cells to paclitaxel and significantly reduced B16 melanoma metast

88 , node-negative, HER2-positive population is paclitaxel and trastuzumab once per week for 12 cycles.

89 Concurrent chemotherapy (carboplatin-paclitaxel) and passively scattered PBT (74-Gy relative

90 in their mechanisms of action, doxorubicin, paclitaxel, and 5-FU all induce rapid and robust upregul

91 ies: anthracycline alone, anthracycline plus paclitaxel, and anthracycline plus docetaxel.

92 received three cycles of IC with cisplatin, paclitaxel, and cetuximab.

93 ly assigned to epirubicin, cyclophosphamide, paclitaxel, and gemcitabine (gemcitabine group; n=1576)

94 xorubicin plus cyclophosphamide, followed by paclitaxel, and had a complete clinical response with re

95 of bioactive compounds (BODIPY, colchicine, paclitaxel, and methotrexate) from membrane-enclosed dep

96 nited States: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (ACTH) and docetaxel, carbop

97 orubicin-cyclophosphamide followed by weekly paclitaxel (arm A) or doxorubicin-cyclophosphamide follo

98 eeks, followed by four cycles of 175 mg/m(2) paclitaxel as a 3 h infusion on day 1 every 3 weeks) or

99 investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative bre

100 ment in overall survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in

101 e show that RSPO3 antagonism synergizes with paclitaxel based chemotherapies in patient-derived xenog

102 fluorphore was chosen as a surrogate for nab-paclitaxel based on its similar molecular weight and alb

103 racil, carboplatin, cisplatin, eribulin, and paclitaxel), based on their continued viability, which w

104 icles could allow reverse engineering of nab-paclitaxel binding antibodies, creating a modular platfo

105 laque calcification, and 2 log orders higher paclitaxel bulk absorption rate-constants.

106 ates increased the maximum tolerated dose of paclitaxel by up to 100-fold following intratracheal ins

107 nonsquamous) or nivolumab 5 or 10 mg/kg plus paclitaxel-carboplatin (all histologies).

108 d, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 6

109 axel-carboplatin, and nivolumab 5 mg/kg plus paclitaxel-carboplatin were 33%, 47%, 47%, and 43%, resp

110 emetrexed-cisplatin, nivolumab 10 mg/kg plus paclitaxel-carboplatin, and nivolumab 5 mg/kg plus pacli

111 line NIVO + IPI followed by carboplatin plus paclitaxel chemotherapy produced an incremental cost eff

112 ose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy, followed by breast-conserving s

113 study (Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Main

114 ral Artery or Popliteal Lesions With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300

115 b was more pronounced in the gemcitabine and paclitaxel cohorts.

116 ntravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrimidine

117 bserved in those receiving seribantumab plus paclitaxel compared with paclitaxel alone (PFS HR, 0.37;

118 ribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients wi

119 d release significantly higher quantities of paclitaxel compared with treatment with nAb-PTX.

120 eased PC3-TXR cell viability with increasing paclitaxel concentration.

121 , whereas modifying MT with GMPCPP or higher paclitaxel concentrations did not affect PFB formation.

122 Herein, we report an amphiphilic DNA-paclitaxel conjugate, which forms stable micellar nanopa

123 576) or to epirubicin, cyclophosphamide, and paclitaxel (control group; n=1576).

124 suggest that buparlisib in combination with paclitaxel could be an effective second-line treatment f

125 addition of 1250 mg/m(2) gemcitabine to the paclitaxel cycles, administered intravenously as a 0.5 h

126 ion low-dose (2-microg/mm(2) surface dose of paclitaxel) DCB.

127 d migratory capabilities of TMD cells, while Paclitaxel decreased the S100A4 level and reduced TMD's

128 e sought to compare the biological effect of paclitaxel delivered by 2 different stent-coating techno

129 MA) displaying more controlled and sustained paclitaxel delivery promise to improve the clinical outc

130 ncing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intrat

131 fects of orbital atherectomy on intraluminal paclitaxel delivery to human peripheral arteries with su

132 Conclusion The addition of seribantumab to paclitaxel did not result in improved PFS in unselected

133 Because of the differences in excipients, paclitaxel dose, and coating morphologies, varying clini

134 ical toxic effects compared with carboplatin-paclitaxel (eg, neutropenia [54% vs 23%; P < .001] and g

135 Paclitaxel-eluting balloon (PEB) angioplasty, stenting,

136 and in 342 (33.1%) in the group receiving a paclitaxel-eluting stent (hazard ratio: 0.96; 95% confid

137 A polymer-free peripheral paclitaxel-eluting stent (PES, Zilver PTX, Cook, IN) has

138 an everolimus-eluting stent compared with a paclitaxel-eluting stent.

139 res was effective only in patients receiving paclitaxel-eluting stents (RD, -7.55 percentage points [

140 0.27%, P=0.02, in patients not treated with paclitaxel-eluting stents), and higher at 30 to 33 month

141 =0.013, in all patients; in patients without paclitaxel-eluting stents, 0.18% versus 0.17%, P=0.91).

142 vents in patients with high scores receiving paclitaxel-eluting stents.

143 rame, and lower in patients not treated with paclitaxel-eluting stents.

144 lowing paclitaxel treatment, indicating that paclitaxel enrichment of chemoresistant CSCs is less dep

145 Encapsulated doxorubicin and paclitaxel exhibit cytotoxic effects on 4T1 and PC3-luc

146 Paclitaxel exhibits its superiority in drug penetration

147 in comparison with PTA, and plasma levels of paclitaxel fall to low levels within 1 hour.

148 received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of consolidation.

149 r 6 weeks followed by the addition of weekly paclitaxel for 12 weeks, followed by 3 cycles of fluorou

150 X-2 inhibitor celecoxib, in combination with paclitaxel, for the management of paclitaxel resistant o

151 regimens: epirubicin, cyclophosphamide, and paclitaxel (four cycles of 90 mg/m(2) intravenously admi

152 eir ability to induce HAC loss revealed that paclitaxel, gemcitabine, dactylolide, LMP400, talazopari

153 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabine (AG).

154 assigned to treatment with PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabi

155 he primary analysis (48 in the olaparib plus paclitaxel group and 46 in the placebo plus paclitaxel g

156 ry in one patient (<1%) in the olaparib plus paclitaxel group and cardiac failure in one patient (<1%

157 or worse adverse events in the olaparib plus paclitaxel group were neutropenia (78 [30%] of 262 patie

158 paclitaxel group and 46 in the placebo plus paclitaxel group).

159 rophil count (40 [15%]); in the placebo plus paclitaxel group, they were neutropenia (59 [23%] of 259

160 ure in one patient (<1%) in the placebo plus paclitaxel group.

161 3728 patients from 48 studies in carboplatin-paclitaxel groups (median age, 63 years; 65% male; 40% s

162 ted with the combination of itraconazole and paclitaxel had significantly decreased tumor weight than

163 Our experimental results suggest that paclitaxel has little effect on biological viability, bu

164 Olaparib combined with paclitaxel has previously shown a significant improvemen

165 5-fluorouracil, hydroxyurea, doxorubicin and paclitaxel have no measurable mutagenic effect.

166 Paclitaxel IC50 in PC3 and PC3-TXR cells was 55.6 and 2,

167 Paclitaxel, ifosfamide, and cisplatin (TIP) achieved com

168 Concomitantly paclitaxel impairs axonal trafficking of RNA-granules an

169 sessed whether the addition of buparlisib to paclitaxel improves clinical outcomes compared with pacl

170 MDR and increased the accumulation of [(3)H]-paclitaxel in ABCB1 overexpressing cells by selectively

171 expression reduced uptake of albumin and nab-paclitaxel in cancer cells and rendered them resistant t

172 Selection for cellular resistance to nab-paclitaxel in cell culture correlated with a loss of Cav

173 oxicity (cardiotoxicity/myelosuppression) of paclitaxel in mice.

174 further enhance the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer.

175 ofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer.

176 between cisplatin-etoposide and carboplatin-paclitaxel in patients with non-small-cell lung cancer r

177 cancer efficacy of nanoparticle-encapsulated paclitaxel in subcutaneous syngeneic mouse melanoma and

178 Pazopanib did not have greater efficacy than paclitaxel in the second-line treatment of urothelial ca

179 FOXM1, KIF20A expression is downregulated by paclitaxel in the sensitive MCF-7 breast cancer cells an

180 d in combination with systemic albumin bound paclitaxel in treatment-refractory breast cancer of the

181 nd's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not CB1 knockout mice.

182 Paclitaxel increased DRG IL-10 receptor expression and t

183 recordings in rat DRG neurons revealed that paclitaxel induced an enhancement of ProTx II (a selecti

184 of neuropathic pain, including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEM

185 administration of exogenous IL-10 attenuated paclitaxel-induced allodynia.

186 cer cells and rendered them resistant to nab-paclitaxel-induced apoptosis.

187 omain interact with axonal IP3R1 and prevent paclitaxel-induced degeneration, while Bcl2 and BclxL ca

188 Paclitaxel-induced mechanical allodynia was prolonged in

189 between WT and Rag1(-/-) mice in severity of paclitaxel-induced mechanical allodynia.

190 e tracked the fate of single PGCCs following paclitaxel-induced mitotic failure.

191 neurons and its functional role in SNI- and paclitaxel-induced neuropathic pain.

192 mouse models of peripheral nerve injury- and paclitaxel-induced neuropathic pain.

193 ls and for endogenous IL-10 in recovery from paclitaxel-induced neuropathy in mice.

194 The mechanisms leading to paclitaxel-induced peripheral neuropathy remain elusive,

195 In vitro, IL-10 suppressed abnormal paclitaxel-induced spontaneous discharges in DRG neurons

196 GAT211 did not impede paclitaxel-induced tumor cell line toxicity.

197 Paclitaxel is a microtubule-stabilizing chemotherapeutic

198 with ethanol lavage followed by infusion of paclitaxel is effective for the treatment of mucinous pa

199 ation with a TLR-7 agonist and albumin bound paclitaxel is effective in inducing disease regression i

200 dominating coronary interventions, although paclitaxel is the only drug on balloon catheters with pr

201 algesia induced by inflammatory mediators or paclitaxel, it eliminates the antihyperalgesic effect of

202 uded ABT-263/crizotinib, ABT-263/paclitaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitaxel/nutlin-3,

203 omes showed that all patients had detectable paclitaxel levels after DCB deployment that declined wit

204 liver, specifically in macrophages, whereas paclitaxel levels in the blood were unchanged after admi

205 e FDA approved, widely used chemotherapeutic paclitaxel, may be promising direction for the field of

206 y assigned to receive either buparlisib plus paclitaxel (n=79) or placebo plus paclitaxel (n=79).

207 lisib plus paclitaxel (n=79) or placebo plus paclitaxel (n=79).

208 a system in which nanoparticle albumin-bound paclitaxel (nAb-PTX) is loaded into a nanoporous solid m

209 cromolar affinity for HSA Peptide 40 and nab-paclitaxel nanoparticles.

210 We found that the DNA-paclitaxel nanostructures enter cells approximately 100

211 litaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitaxel/nutlin-3, all of which exhibited synergistic

212 Treatment of prostate cancer with paclitaxel often fails due to the development of chemore

213 in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increa

214 receiving radiotherapy (RT) with carboplatin-paclitaxel or cisplatin-etoposide were identified using

215 nib in combination with taxane chemotherapy (paclitaxel or docetaxel) for 24 weeks.

216 -dose NSC23925b alone or in combination with paclitaxel or doxorubicin were conducted in male BALB/c

217 zed CRPC cells toward chemotherapies such as paclitaxel or doxorubicin.

218 chemotherapeutic agents dichloroacetate and paclitaxel or HIV envelope protein gp120.

219 tly affected (p < 0.05) after treatment with paclitaxel or nocodazole due to changes in the MTs netwo

220 itubulin cancer drugs eribulin, ixabepilone, paclitaxel, or vinorelbine at MTDs.

221 slation included ABT-263/crizotinib, ABT-263/paclitaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitax

222 Correspondingly, fluorescent paclitaxel penetrated deeper in OAS-treated femoropoplit

223 py with daily image guidance plus 30 mg/m(2) paclitaxel per week concomitantly.

224 Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured after las

225 weeks) or epirubicin, cyclophosphamide, and paclitaxel plus gemcitabine (the same chemotherapy regim

226 ients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus pl

227 An investigational arm of paclitaxel plus lapatinib (TL) was closed early.

228 ned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62).

229 orubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab followed by trastuzumab alon

230 Moreover, DHM markedly sensitized paclitaxel (PTX) and doxorubicin (DOX) resistant ovarian

231 id nanosystem (LPN) was fabricated to coload paclitaxel (PTX) and tetrandrine (TET) at a precise comb

232 ) for integrin alphavbeta3 receptor targeted paclitaxel (PTX) delivery in lung cancer cells and its i

233 luorescein-maleimide and the medicinal agent paclitaxel (PTX) into cells.

234 Paclitaxel (PTX) is one of the most successful drugs eve

235 Paclitaxel (PTX) is one of the most useful chemotherapeu

236 Paclitaxel (PTX) loaded BCM (BCM-PTX) exhibited higher s

237 situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC).

238 f aggregation-induced emission (AIE), hybrid paclitaxel (PTX) nanocrystals integrated with tetrapheny

239 limitations, we conjugated the chemotherapy paclitaxel (PTX) to a dendritic polyglycerol sulfate (dP

240 -soluble anticancer agents and have advanced paclitaxel (PTX) to humans due to drug solubilization, b

241 bumin-coated nanocrystal (NC) formulation of paclitaxel (PTX) with 90% drug loading and high serum st

242 s of cisplatin (DDP), bevacizumab (BEV), and paclitaxel (PTX) with conventional and two levels ("equi

243 ith SKOV-3 xenografts) showed that (i) drug (paclitaxel (PTX)) could be attached to MENs (30-nm CoFe2

244 Here we describe the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to

245 ctive was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometria

246 del utilizing the frontline anticancer drug, paclitaxel (PTX).

247 ovarian A2780 and OVCAR4) were treated with paclitaxel (PTX, 2-1000nM) or doxorubicin (DOX, 20-1000n

248 ation of these small neutral NPs loaded with paclitaxel (PTX-NPs), but not anionic PTX-NPs, slowed th

249 oxic effect profiles favored the carboplatin-paclitaxel regimen.

250 Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable effi

251 f Nav1.7 protein in DRGs from male rats with paclitaxel-related CIPN and from male and female humans

252 e insights into the underlying mechanisms of paclitaxel resistance and have implications for the deve

253 ion with rubone, demonstrating a reversal of paclitaxel resistance by rubone.

254 rs and novel chemotherapeutic strategies for paclitaxel resistance.

255 HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells.

256 ation with paclitaxel, for the management of paclitaxel resistant oral cancer cells.

257 7 breast cancer cells and deregulated in the paclitaxel-resistant MCF-7Tax(R) cells.

258 tivation of caspase-3 and cleavage of HuR in paclitaxel-resistant oral cancer cells, both in vitro an

259 upregulation of miR-34a and chemosensitizes paclitaxel-resistant prostate cancer cells, killing both

260 ce the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer.

261 rotein levels correlated positively with nab-paclitaxel sensitivity.

262 Moreover, treatment with gemcitabine and nab-paclitaxel significantly reduces the overall number of m

263 eously or subsequent to the chemotherapeutic paclitaxel; simultaneous treatment more effectively supp

264 ied by decreased sensitivity of the cells to paclitaxel, suggesting a role of mechanotransduction in

265 Reduction of microtubule growth with paclitaxel suppresses GFP-Kif15 motility, demonstrating

266 The anticancer drug paclitaxel (Taxol) exhibits paradoxical and poorly under

267 Finally, we report that Paclitaxel/taxol promotes mitotic rounding and subsequen

268 cancer therapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and

269 bepilone, we observed delayed recovery after paclitaxel that produced a more severe, pervasive, and p

270 do" kinetic stabilization, characteristic of paclitaxel, that nearly eliminates the energy difference

271 d resistance to the antitumor effects of nab-paclitaxel therapy.

272 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no significant difference in media

273 h undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.57, P

274 Conjugation of paclitaxel to both PEG sizes significantly enhanced its

275 Administration of low-dose paclitaxel to established (EGI-1) and primary (CCA-TV3)

276 Nab-paclitaxel, a nanoparticle conjugate of paclitaxel to human albumin, exhibits efficacy in pancre

277 se and monoacylglycerol lipase inhibitors in paclitaxel-treated mice.

278 s increased in dorsal root ganglia (DRGs) of paclitaxel-treated rats.

279 Moreover, injured paclitaxel-treated zebrafish skin and scratch-wounded hu

280 ession sensitized the breast cancer cells to paclitaxel treatment by inhibiting beta-catenin and PKM2

281 Paclitaxel treatment increased the number of T cells in

282 context-dependent response is observed with paclitaxel treatment increasing the CSC related genes in

283 oss all MDA-MB-231 in vitro models following paclitaxel treatment, indicating that paclitaxel enrichm

284 Crucially, resembling paclitaxel treatment, silencing of FOXM1 and KIF20A simi

285 Disintegration can be suppressed by paclitaxel treatment.

286 Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by altering IP3 receptor phosph

287 the synergistic effects of itraconazole and paclitaxel using orthotopic mouse models with establishe

288 Paclitaxel was administered i.v. at 50 mg/m and i.p. at

289 The cytotoxic potency of the released paclitaxel was also confirmed in tumor cells cultured wi

290 Downregulation of nuclear S100A4 by low-dose paclitaxel was associated with a strong reduction in Rho

291 ents who did not receive bevacizumab, weekly paclitaxel was associated with progression-free survival

292 Response of the surrogates to treatment with paclitaxel was measured by optical imaging and by analys

293 This effect of low-dose paclitaxel was reproduced by ginkolic acid, a specific S

294 locks binding of all three antibodies to nab-paclitaxel when added in excess.

295 by treatment with the chemotherapeutic agent paclitaxel (which induces hypersensitivity to mechanical

296 le in complexity to natural products such as paclitaxel while requiring only 2-4 simple synthetic ste

297 randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) followe

298 d concurrent chemotherapy of carboplatin and paclitaxel with or without cetuximab, and 60- versus 74-

299 Cardiac toxic effects from paclitaxel with trastuzumab, manifesting as grade 3 or 4

300 therapy-induced neuropathic pain produced by paclitaxel without producing tolerance.